Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q2 2021 call → NOWe need to determine if management conveys that the business right now is visibly outgrowing the company's own size. Look for statements about current activity, demand, commitments that are large relative to company size. The company is small (Catalyst Pharmaceuticals, a rare disease company with one main product Firdapse). They report revenue growth, but is there a sense of disproportion? They mention new patient enrollments up 111% vs same quarter last year, but that's growth. They talk about expanding portfolio, acquisitions, but that's future. They mention they are evaluating opportunities, but not yet committed. They mention they have $155M cash, growing. They talk about potential acquisitions before end of year, but that's prospective. They mention they are preparing to amend complaint, etc. No explicit statement that current business is disproportionately large relative to company size. They do say "we are optimistic that as the country continues to recover... revenue trajectory will ramp further upward" but that's future. They mention "we have a robust pipeline of patient leads" but that's potential. They mention "we are handling, preparing for, or committing to volumes" - not really. They mention "the same absolute wins keep translating into outsized percentage change because the base is still small" - they do report 14% growth, 111% new patient enrollments, but that's growth, not necessarily disproportion. They don't explicitly contrast company size with scale of what's arriving. They talk about expanding into new therapeutic areas, but that's future. So answer NO. Check if any statement like "this is a small company and this deal is huge" - not present. They mention "we are hoping to complete one or more company or product acquisitions before the end of this year" - that's prospective. They mention "we have $155M cash" but that's not about current business arriving. So NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.